The regulatory control of non-steroidal anti-inflammatory agents
Tóm tắt
The number of marketed non-steroidal anti-inflammatory agents varies widely from one European country to another, partly as a consequence of differing regulatory policies. During a four-year period, nine of 18 applications to market such drugs in the Netherlands failed; the remaining nine compounds were all licenced; in all, 22 single drug entities of this type are currently on sale. In Norway during the same period none of the 15 applications received was granted, though five cases are still pending; only seven such drugs are currently licenced for sale. The reasons for the national decisions and for the discrepancies between them are analyzed. A study of the prescribing practice of rheumatologists in the two countries suggests that some 10 to 15 products of this type are in fact needed in order to provide a reasonable choice. Current registration trends could markedly discourage further research investment in this field unless in the near future a basis is found for developing non-steroidal anti-inflammatory drugs with distinct advantages as compared with all those so far known.
Từ khóa
Tài liệu tham khảo
Valkenburg HA (1979) Frequentie en aard van reumatische aandoeningen in de bevolking. In: Reumatiek en pijnbestrijding. Ciba-Geigy BV, Arnhem, pp. 9–19
Dukes MNG, Lunde I (1979) Measuring the repercussions of drug control: an emerging challenge. Pharm J 223: 511–513
Dukes MNG, Lunde I (1979) Controls, common sense and communities. Pharm Weekbl 114: 1283–1294
Lunde I, Dukes MNG (1980) Les répercussions du contrôle administratif des médicaments (text in French and English). Ind Santé 49: 37–57
Ballin JC (1979) Who makes the therapeutic decisions? J Am Med Assoc 242: 2875
Jøldal B (1974) Norwegian drug control, organization and tasks. In: Moe M (ed) Report from the Norwegian Drug monopoly. Oslo, pp 32–43 (in Norwegian)
Ŝvihovec J (1980) Anti-inflammatory analgesics and drugs used in gout. In: Dukes MNG (ed) Meyler's side effects of drugs, 9th edn. Excerpta Medica, Amsterdam Oxford
Fenner H (1980) Neue nichtsteroide Antirheumatika — machen sie die Therapie risikoärmer? Dtsch Apoth Ztg 120: 987–992
Davies DM (ed) (1977) Textbook of adverse drug reactions. Oxford, p 45
Simon LS, Mills JA (1980) New nonsteroidal anti-inflammatory drugs, II. N Engl J Med 302: 1237–1243
Steward F, Wibberley G (1980) Drug innovation — what's slowing it down? Nature 284: 118–120
Mowat AG (1980) Rheumatoid arthritis. Pharm J 224: 412–416
Huskisson EC, Woolf DL, Balme HW, Scott J, Franklyn S (1976) Four new anti-inflammatory drugs: response and variations. Br Med J 2: 1048–1049
Gumpel JM (1978) Which anti-inflammatory drugs in rheumatoid arthritis? Br Med J 3: 256
Anon. (1977) A.M.A. Drug evaluations. PSG Publishing Comp. Littleton, MA, p 375
Hart FD (1980) Rheumatic disorders. In: Avery GS (ed) Drug treatment. Adis Press, Sydney New York, p 864
Simonian S, van Gessel HM, Beekhof HG (1980) Carcinogenicity and mutagenicity data on drugs: a retrospective analysis (in press)
Bertens AM (1980) Personal communication, based on data available to the Netherlands Council of Health Funds (Ziekenfondsraad)
Øydvin K (1978) Legemiddelforbruket i Norge. Norsk Medisinaldepot, Oslo
Vinegar R (1979) Discussion remark cited in: Beers RF, Bassett EG (eds) Mechanisms of pain and analgesic compounds. Raven Press, New York, p 323
Løkken P, Skjelbred P (1980) Analgesic and anti-inflammatory effects of paracetamol evaluated by bilateral oral surgery. Br J Clin Pharmacol (in press)
Simon LS, Mills JA (1980) Nonsteroidal antiinflammatory drugs I. N Engl J Med 302: 1179–1185
Wright V, Amos R (1980) Do drugs change the course of rheumatoid arthritis? Br Med J 2: 964–966
Anastassiades TP, Dwosh IL, Ford PM (1980) Progressive rheumatoid arthritis: how far should we go with medical therapy? Can Med Assoc J 122: 1223–1224